U.S. Markets closed

Wired News – Biogen to Present Data from Alzheimer’s Disease Clinical Development Portfolio at AAIC in Chicago

Stock Monitor: Orgenesis Post Earnings Reporting

LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free research report on Biogen Inc. (NASDAQ: BIIB), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BIIB as the Company’s latest news hit the wire. On July 18, 2018, the Company declared that it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC), to be held in Chicago on July 22-26, 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Orgenesis Inc. (NASDAQ: ORGS), which also belongs to the Healthcare sector as the Company Biogen. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Biogen most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Biogen and Eisai will Present Details from Phase-2 Clinical Study of BAN2401

Biogen will present a new analysis from the Phase-1b (PRIME) study of aducanumab, which is an investigational anti-amyloid beta antibody therapy for mild cognitive impairment (MCI) due to Alzheimer’s disease and mild dementia due to Alzheimer’s disease. As of October 2017, aducanumab is being co-developed with Eisai Co. Ltd. In addition, Eisai will present the top-line Phase-2 clinical study results of BAN2401, which is an anti-amyloid beta protofibril antibody; and data on elenbecestat, which is a beta amyloid cleaving enzyme (BACE) inhibitor.

Highlights of Presentations

Alzheimer’s disease investigational therapies:

  • 24-month analysis of APOE Epsilon4 carriers in PRIME, which is a randomized Phase-1b study of aducanumab
  • Elenbecestat, which is a novel BACE inhibitor, demonstrating similar pharmacokinetics and safety in Japanese subjects during multiple dosings as in other studies
  • 24-month analysis of change from baseline in clinical dementia rating scale cognitive and functional domains in PRIME, which is a randomized Phase-1b study of aducanumab
  • Treatment of early AD subjects with BAN2401, which significantly clears amyloid plaque and reduces clinical decline
  • Elenbecestat, E2609, which is a BACE Inhibitor - Results from a Phase-2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer’s disease
  • Lumipulse® G Total Tau to Beta-Amyloid 1-42 ratio cut-point determination for amyloid eligibility screening
  • Anti-Tau Antibody BIIB092 binds secreted Tau in pre-clinical models and Alzheimer’s disease cerebrospinal fluid

General Alzheimer’s disease research:

  • Cognitive and other neuropsychological assessments documented in electronic health records prior to, or at Alzheimer’s disease diagnosis
  • Supporting disease modification via analyses of the link between clinical endpoints and biomarkers in Alzheimer’s disease clinical trials
  • Translational research - the view from Pharma
  • Cognitive reserve modulates the association of cerebral amyloid pathology with cognitive performance in persons with Alzheimer’s disease dementia
  • Alzheimer’s disease patient and caregiver engagement initiative - Determining what matters most to Alzheimer’s patients and care partners to inform the design and development of new therapies; determinations of payment and coverage; and the delivery of care and services

Biogen’s Alzheimer’s Disease Clinical Program

Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. More than 40 million people worldwide are living with Alzheimer’s disease and related dementias. Alzheimer’s disease is usually diagnosed in people aged 65 and older, but it starts earlier with subtle neurological changes occurring years or even decades before symptoms appear. With an emphasis on early-stage disease, Biogen’s research programs target several of the identified causes, amyloid and tau pathology- proteins believed to play a critical role in Alzheimer’s disease development. These programs range from pre-clinical experiments to Phase-3 clinical trials. Biogen’s Alzheimer’s disease candidate, currently under development, is aducanumab, which is the first investigational drug to slow progression and reduce biological evidence of disease in an early clinical trial.

About Aducanumab

Aducanumab (BIIB037) is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called RTM. Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement with Eisai. The US Food and Drug Administration (FDA) has granted a Fast Track designation for the development of aducanumab.

About BAN2401 and Elenbecestat

BAN2401 is a humanized monoclonal antibody for Alzheimer’s disease that is the result of a strategic research alliance between Eisai and BioArctic. BAN2401 selectively binds to neutralize and eliminate soluble, toxic ABeta aggregates that are thought to contribute to the neurodegenerative process in Alzheimer’s disease. As such, BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease.

Elenbecestat is an oral BACE inhibitor currently being investigated in Phase-3 clinical studies for Alzheimer’s disease discovered by Eisai and in collaboration with Biogen. By inhibiting BACE, elenbecestat reduces ABeta production, which is thought to lead to a reduction in amyloid plaque formations caused by the aggregation of toxic oligomers and protofibrils in the brain. The FDA has granted a Fast Track designation for the development of elenbecestat.

About Biogen Inc.

Headquartered in Cambridge, Massachusetts, Biogen is a biotechnology organization developing, marketing, and manufacturing therapies for people living with serious neurological, autoimmune, and rare diseases. The Company has the leading portfolio of medicines to treat multiple sclerosis (MS); has the first and only approved treatment for spinal muscular atrophy (SMA); and is at the forefront of research into new medicines for neurological and neurodegenerative conditions.

Stock Performance Snapshot

July 19, 2018 - At Thursday’s closing bell, Biogen’s stock marginally dropped 0.11%, ending the trading session at $358.11.

Volume traded for the day: 1.64 million shares.

Stock performance in the last month – up 22.62%; previous three-month period – up 34.62%; past twelve-month period – up 27.01%; and year-to-date - up 12.41%

After yesterday’s close, Biogen’s market cap was at $75.70 billion.

Price to Earnings (P/E) ratio was at 18.33.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors